Dr. David Yaden offers his perspective on the “real risks and benefits of psychedelics” after the FDA’s rejection of MDMA for the treatment of PTSD. He hopes that public sentiment will become more “balanced and nuanced” regarding the state of evidence on psychedelics as medicine.
After FDA setback, psychedelic drugmakers distance themselves from a pioneer
Previous
Previous
The State of Psychedelics
Next
Next

